In a woman with acute heavy vaginal bleeding, how should tranexamic acid (TXA) be administered and what are its contraindications?

Tranexamic Acid for Vaginal Bleeding

For postpartum hemorrhage after vaginal delivery, administer tranexamic acid 1 g intravenously over 10 minutes as soon as PPH is diagnosed (blood loss >500 mL or hemodynamic compromise), with a second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours—but only if given within 3 hours of birth. 1

Administration Protocol

Dosing Regimen

• First dose: 1 g (100 mg/mL) intravenously at 1 mL/min (infused over 10 minutes) 1
• Second dose: 1 g intravenously if bleeding continues after 30 minutes OR if bleeding restarts within 24 hours of completing the first dose 1
• Critical timing: Must be administered within 3 hours of birth—benefit decreases by 10% for every 15-minute delay, with no benefit and potential harm beyond 3 hours 1

Clinical Indication Threshold

Tranexamic acid should be given for clinically diagnosed postpartum hemorrhage, defined as: 1

• Blood loss >500 mL after vaginal birth, OR
• Any blood loss sufficient to compromise hemodynamic stability

Important Context

• Give regardless of cause: Administer TXA for all cases of PPH, whether due to genital tract trauma, uterine atony, or other reasons 1
• Part of comprehensive care: Use TXA in addition to (not instead of) standard PPH management including uterotonics, fluid replacement, and other interventions as needed 1
• Earlier is better: The sooner TXA is given after birth, the greater the mortality benefit—administer as soon as PPH is diagnosed 1

Contraindications

Absolute Contraindications

• Known thromboembolic event during pregnancy 1
• Active intravascular clotting 2
• Subarachnoid hemorrhage (risk of cerebral edema and infarction) 2
• Severe hypersensitivity to tranexamic acid 2

Critical Safety Warnings

• DO NOT administer beyond 3 hours after birth—this is suspected to be potentially harmful rather than beneficial 1
• Intravenous route ONLY—inadvertent intrathecal administration has caused maternal deaths from seizures and cardiac arrhythmias 2, 3
• Infusion rate matters: Infuse no faster than 1 mL/minute to avoid hypotension 2

Dose Adjustments for Renal Impairment

For patients with renal dysfunction, reduce dosing as follows: 2

• Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
• Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
• Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours

Evidence Strength and Nuances

The WHO strong recommendation is based primarily on the WOMAN trial, which enrolled over 20,000 women across 21 countries and demonstrated that early TXA use reduces maternal death from bleeding by 19% in women with established PPH. 1 This represents high-quality evidence for treatment of PPH.

Important distinction: While TXA is strongly recommended for treating established PPH, recent high-quality evidence shows it is not effective for preventing PPH when given prophylactically to all women during vaginal delivery. 4 The prophylactic use resulted in little to no difference in blood loss ≥500 mL or ≥1000 mL compared to placebo.

Common Pitfalls to Avoid

• Timing error: Do not delay administration while waiting for laboratory confirmation—clinical diagnosis is sufficient 1
• Route confusion: Ensure proper labeling and administration protocols to prevent catastrophic intrathecal injection 2, 3
• Late administration: Do not give TXA if more than 3 hours have elapsed since birth 1
• Withholding due to thrombosis concerns: The evidence shows TXA does not increase thromboembolic risk in the PPH setting 5, 6
• Using as monotherapy: Always combine with standard PPH management including uterotonics 1